1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia

Technology appraisal guidance [TA541] Published: 19 September 2018

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Evidence

Review and download supporting evidence. Includes the full guideline if available.

Supporting evidence

  • Evaluation report  
  • Final appraisal determination committee papers PDF 1.07 MB 19 September 2018  
  • Appraisal consultation committee papers PDF 6.79 MB 19 September 2018